ABK-EGFR-1 / Abbisko - LARVOL DELTA

Discovery and characterization of ABK-EGFR-1, a 4th generation EGFR C797S Inhibitor with excellent selectivity and brain penetration (AACR 2026) - "ABK-EGFR-1 is a novel next-generation EGFR C797S inhibitor with enhanced selectivity over wild-type EGFR and robust CNS penetration. It demonstrates strong in vivo efficacy across multiple EGFR C797S-driven xenograft models and possesses favorable drug-like properties. Collectively, these findings support the continued preclinical development of ABK-EGFR-1 and its advancement toward clinical evaluation."

Late-breaking abstract • Oncology

Abbisko Therapeutics…announced that six preclinical study updates from its proprietary pipeline have been selected for poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting (Abbisko Therap Press Release)

Preclinical • Solid Tumor